Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-06-12
Target enrollment:
Participant gender:
Summary
Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate
to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic
drugs (DMARD) including methotrexate (MTX).